- Home
- HE vs MRVI Comparison
HE vs MRVI Comparison
Compare HE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | MRVI |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 449.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HE | MRVI |
|---|---|---|
| Price | $13.77 | $3.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $11.50 | $4.57 |
| AVG Volume (30 Days) | ★ 5.4M | 1.3M |
| Earning Date | 02-20-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $3,080,252,000.00 | $192,435,000.00 |
| Revenue This Year | $12.61 | N/A |
| Revenue Next Year | $1.96 | $9.04 |
| P/E Ratio | $155.05 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $8.14 | $1.67 |
| 52 Week High | $13.91 | $6.21 |
Technical Indicators
Market Signals| Indicator | HE | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 70.10 | 61.96 |
| Support Level | $12.21 | $3.19 |
| Resistance Level | $13.91 | $4.02 |
| Average True Range (ATR) | 0.48 | 0.17 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 93.53 | 78.18 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.